103 related articles for article (PubMed ID: 9255101)
1. A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy.
Mackey R
Br J Obstet Gynaecol; 1997 Aug; 104(8):973-4. PubMed ID: 9255101
[No Abstract] [Full Text] [Related]
2. A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy.
Adachi JD; Sargeant EJ; Sagle MA; Lamont D; Fawcett PD; Bensen WG; McQueen M; Nazir DJ; Goldsmith CH
Br J Obstet Gynaecol; 1997 Jan; 104(1):64-70. PubMed ID: 8988699
[TBL] [Abstract][Full Text] [Related]
3. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate.
Prior JC; Vigna YM; Wark JD; Eyre DR; Lentle BC; Li DK; Ebeling PR; Atley L
J Bone Miner Res; 1997 Nov; 12(11):1851-63. PubMed ID: 9383690
[TBL] [Abstract][Full Text] [Related]
4. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
6. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
Cauley JA; Robbins J; Chen Z; Cummings SR; Jackson RD; LaCroix AZ; LeBoff M; Lewis CE; McGowan J; Neuner J; Pettinger M; Stefanick ML; Wactawski-Wende J; Watts NB;
JAMA; 2003 Oct; 290(13):1729-38. PubMed ID: 14519707
[TBL] [Abstract][Full Text] [Related]
7. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial.
Grey AB; Stapleton JP; Evans MC; Tatnell MA; Reid IR
Ann Intern Med; 1996 Sep; 125(5):360-8. PubMed ID: 8702086
[TBL] [Abstract][Full Text] [Related]
8. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy.
Bush TL
Eur Heart J; 1996 Aug; 17 Suppl D():9-14. PubMed ID: 8869876
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
Greenspan SL; Resnick NM; Parker RA
JAMA; 2003 May; 289(19):2525-33. PubMed ID: 12759324
[TBL] [Abstract][Full Text] [Related]
10. Balancing between observational studies and randomized trials in prevention of coronary heart disease by estrogen replacement: HERS study was no revolution.
Ylikorkala O
Acta Obstet Gynecol Scand; 2000 Dec; 79(12):1029-36. PubMed ID: 11130082
[No Abstract] [Full Text] [Related]
11. Bhathena RK, Anklesaria BS, Ganatra AM, Pinto R. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins. Br J Clin Pharmacol 1998 Feb; 45 (2): 170-172.
Kneer-Aronoff C
J Womens Health; 1998 Oct; 7(8):1054-5. PubMed ID: 10026007
[No Abstract] [Full Text] [Related]
12. Consortium for the Assessment of Research on Progestins and Estrogens (CARPE) Fort Worth, Texas August 1-3, 2003.
Simpkins JW; Singh M
J Womens Health (Larchmt); 2004 Dec; 13(10):1165-8. PubMed ID: 15650349
[No Abstract] [Full Text] [Related]
13. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Rapp SR; Espeland MA; Shumaker SA; Henderson VW; Brunner RL; Manson JE; Gass ML; Stefanick ML; Lane DS; Hays J; Johnson KC; Coker LH; Dailey M; Bowen D;
JAMA; 2003 May; 289(20):2663-72. PubMed ID: 12771113
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy should be administered as secondary prevention of coronary artery disease.
Spencer AP
Pharmacotherapy; 2000 Sep; 20(9):1028-33. PubMed ID: 10999493
[TBL] [Abstract][Full Text] [Related]
15. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.
Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
JAMA; 2002 May 22-29; 287(20):2668-76. PubMed ID: 12020302
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study.
Bassaw K; Gangar K
Br J Obstet Gynaecol; 1997 Jun; 104(6):758-9. PubMed ID: 9197894
[No Abstract] [Full Text] [Related]
17. Postmenopausal hormone replacement therapy and plasma lipoproteins.
Taskinen MR
J Intern Med; 1995 Nov; 238(5):385-7. PubMed ID: 7595177
[No Abstract] [Full Text] [Related]
18. Effects of exercise training added to ongoing hormone replacement therapy on bone mineral density in frail elderly women.
Villareal DT; Binder EF; Yarasheski KE; Williams DB; Brown M; Sinacore DR; Kohrt WM
J Am Geriatr Soc; 2003 Jul; 51(7):985-90. PubMed ID: 12834519
[TBL] [Abstract][Full Text] [Related]
19. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
20. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease.
Herrington DM; Werbel BL; Riley WA; Pusser BE; Morgan TM
J Am Coll Cardiol; 1999 Jun; 33(7):2030-7. PubMed ID: 10362210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
